ClinicalTrials.gg
RecruitingNCT07937540AI-PRESENCE HFUpdated Nov 16, 2026

Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure

An interventional study of SGLT2 Inhibitor Educational Video in Heart Failure Patients and Heart Failure, sponsored by Keimyung University Dongsan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Keimyung University Dongsan Medical Center · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 148 studies in Heart Failure with a site in Korea, Republic of — 49 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.

Planned enrollment
66th of 109
150 · median 227
Started
2026
with 17 others
No phase
33 of 148
13 open now
Primary completion
2027-07
later than 17 of 53 live
Registered
148th of 148
by date

Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 66th largest by planned enrollment of the 109 interventional ones that give a count, is one of 18 that started in 2026, is one of 33 with no phase, reaches primary completion later than 17 of the 53 other live ones, and was the 148th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

49 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Heart Failure with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of the primary attending physician's presence in educational videos on patient satisfaction and educational effectiveness.

Read the detailed description

The videos, generated using AI technology, focus on SGLT2 inhibitors and are provided to heart failure patients during their outpatient clinic waiting time.

In this single-center, randomized, 2x2 factorial study, participants will be assigned to one of four groups based on two factors: the specific doctor featured in the video (Doctor A vs. Doctor B) and the physician's role presentation (presented as the patient's actual attending physician vs. a non-attending general cardiologist).

All participants will watch the assigned educational video during their waiting time and then proceed with their scheduled outpatient consultation. After the consultation, participants will complete a single survey. The survey will assess overall patient satisfaction, the perceived usefulness of the education, and the objective understanding of the video's key messages regarding heart failure management and SGLT2 inhibitors.

03

Conditions studied

  • Heart Failure Patients
  • Heart Failure

Browse trials for

Keywords

  • Patient Education
  • Health Literacy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 years or older.
  • Patients diagnosed with heart failure or those visiting the cardiology outpatient clinic with suspected heart failure symptoms (e.g., dyspnea, edema).
  • Patients currently taking or scheduled to be prescribed SGLT2 inhibitors for the treatment of heart failure.
  • Patients who are able to watch the educational video during the outpatient waiting time and complete the survey after the consultation.
  • Patients who fully understand the purpose and procedures of this study and voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients who do not understand the contents of this study or do not consent to the study due to cognitive decline, etc.
  • Patients with expected acute exacerbation of heart failure or a of 1 year or less.
  • Patients who have difficulty watching the video due to visual or hearing impairments.
  • Patients scheduled for heart failure-related surgery or procedures.
  • Patients who are currently participating in, or have participated in within the past 6 months, another intervention study related to heart failure education.
  • Other patients deemed inappropriate for study participation by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Doctor A - Attending Physician Video

    Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as their primary physician.

    Behavioral: SGLT2 Inhibitor Educational Video

  • Active comparator
    Doctor A - Non-Attending Physician Video

    Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as a general cardiologist (non-attending).

    Behavioral: SGLT2 Inhibitor Educational Video

  • Experimental
    Doctor B - Attending Physician Video

    Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as their primary physician.

    Behavioral: SGLT2 Inhibitor Educational Video

  • Active comparator
    Doctor B - Non-Attending Physician Video

    Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as a general cardiologist (non-attending).

    Behavioral: SGLT2 Inhibitor Educational Video

Interventions

  • BehavioralSGLT2 Inhibitor Educational Video

    Participants will watch a standardized, AI-synthesized educational video focusing on SGLT2 inhibitors and heart failure management during their outpatient waiting time. The core educational content and video duration are identical across all study groups. Depending on the assigned arm, the video will feature the AI-synthesized face and voice of either Doctor A or Doctor B. Prior to viewing, the research assistant will introduce the physician in the video either as the patient's actual attending physician or as a general cardiologist(non-attending physician), according to the 2x2 factorial randomization.

    Also known as: Outpatient Waiting Time Education, AI-Synthesized Physician Video

06

What researchers measure

Primary outcomes

  1. Patient Satisfaction Score

    Patient satisfaction regarding the positive impact and helpfulness of the educational video on the subsequent outpatient consultation process. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates a higher level of patient satisfaction.

    Time frame: Immediately after the outpatient clinic visit (Day 0)

  2. Educational Usefulness Score

    The perceived usefulness of the educational video in understanding heart failure treatment methods, specifically the role, effects, and precautions of SGLT2 inhibitors. It is assessed using a 5-point Likert scale ranging from 1 to 5. A higher score indicates greater perceived educational usefulness and understanding.

    Time frame: Immediately after the outpatient clinic visit (Day 0)

Secondary outcomes

  1. Educational Content Delivery Effectiveness Score

    An objective assessment of the patient's understanding of the video's key messages, such as heart failure management and SGLT2 inhibitor information. It is evaluated based on the number of correct answers to 4 multiple-choice questions derived directly from the video's core content. The total score ranges from 0 to 4, where 1 point is awarded for each correct answer. A higher score indicates a better understanding and a higher level of correct knowledge acquisition.

    Time frame: Immediately after the outpatient clinic visit (Day 0)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 11 months is below that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Aug 21, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937540
Lead sponsor
Keimyung University Dongsan Medical Center
Responsible party
In-Cheol Kim (Associate Professor, Keimyung University Dongsan Medical Center) — Principal investigator
First posted
Nov 16, 2026
Start date
Aug 21, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Incheol Kim, MD
Contact
kimic@dsmc.or.kr
+82-53-258-4625

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion